Last updated: February 23, 2026
What Is NDC 51407-0020?
NDC 51407-0020 is a drug product identified under the National Drug Code (NDC) system. Based on available data, it is the Zolgensma (onasemnogene abeparvovec-xioi) injection, designated for the treatment of spinal muscular atrophy (SMA). Zolgensma is a gene therapy approved by the FDA in May 2019 for pediatric patients under two years old.
Current Market Position
Market Size
The SMA gene therapy market is driven by diagnosis rates and treatment adoption. Key factors include:
- Patient Population: Approx. 1 in 10,000 live births globally, with variability across regions.
- Treatment Penetration: Limited by diagnosis delays, cost, and regulatory access.
Sales Data
- 2022 Sales: Estimated at $1.5 billion globally, with the United States accounting for approximately 75% of revenues.
- Market Share: Zolgensma maintains about 70-80% of the SMA gene therapy market share in the U.S., competing mainly with Spinraza (nusinersen) and Evrysdi (risdiplam).
Usage Trends
- Approval extensions and expanded indications have increased treatment candidate pools.
- The drug is administered as a one-time intravenous infusion, which affects patient compliance and market expansion potential.
Price Structure and Reimbursement
List Price
- U.S. Average Wholesale Price (AWP): Approximately $2.125 million per dose.
- Pricing by Region: Prices in Europe and Asia are lower, ranging from $1.5 million to $2 million, influenced by negotiated discounts and reimbursement policies.
Reimbursement and Cost Effectiveness
- The high price prompts payer negotiations and value-based agreements.
- Payer coverage is generally favorable in the U.S., with many insurers reimbursing fully or through special access programs.
Competitive Landscape
| Product |
Approval Year |
Treatment Modality |
Approx. Market Share (2022) |
Price (USD) |
| Zolgensma (NDC 51407-0020) |
2019 |
Gene therapy |
70-80% |
$2.125 million |
| Spinraza (nusinersen) |
2016 |
Antisense oligonucleotide |
15-25% |
$750,000 per year |
| Evrysdi (risdiplam) |
2020 |
Small molecule |
5-10% |
$340,000 per year |
Market Projections
Short-Term (2023-2025)
- Growth Rate: 15-20% annually, primarily driven by new approvals and expanding indications.
- Revenue: Projected sales of $1.8–2.2 billion in 2023; $2.2–2.6 billion by 2025.
- Price Trends: Expected to remain stable due to high treatment cost but could see discounts in negotiated markets.
Long-Term (2026-2030)
- Market Penetration: Increased access in emerging markets and broader age indication approvals.
- Price Pressure: Possible reduction driven by biosimilars (not applicable for gene therapies currently) and government negotiation policies.
- Innovations: Development of next-generation gene therapies may influence pricing and market dynamics.
Price Sensitivity and Access
The primary concern remains the high upfront cost balanced against the potential for long-term cost savings and clinical outcomes. Payers favor outcome-based agreements and installment payment models.
Key Drivers of Market Dynamics
- Regulatory decisions expanding indications.
- Insurance reimbursement policies adapting to the high-cost therapy.
- Market entry of generics/biosimilars, unlikely for gene therapies soon due to patent protections and manufacturing complexity.
- Advances in gene editing techniques could affect future therapies.
Summary
NDC 51407-0020 (Zolgensma) is a high-value, high-price gene therapy dominating the SMA treatment market since 2019. Sales are projected to grow annually at 15-20%, sustained by expanding indications and diagnosis rates. Price stability reflects its current patent and manufacturing complexity, although long-term pricing may be affected by policy and technological developments.
Key Takeaways
- The majority of revenue is concentrated in the U.S. with prices around $2.125 million.
- Market growth is driven by increased diagnosis and indications.
- Competitive threats remain limited in the short term, but long-term market dynamics may shift with innovations.
- Reimbursement strategies are crucial for market access and pricing sustainability.
- Price projections anticipate stability but with potential downward adjustments due to policy changes.
FAQs
1. What factors influence the price of NDC 51407-0020?
Drug pricing is influenced by manufacturing costs, regulatory exclusivity, market access negotiations, and payer reimbursement policies.
2. How does the patient population impact sales projections?
Larger diagnosed patient pools and expanded indications increase potential treatments, driving revenue growth.
3. Are biosimilars or generics expected for gene therapies like Zolgensma?
Currently, gene therapies like Zolgensma are protected by patents, making generic biosimilars unlikely in the near term.
4. What are the main barriers to market expansion for Zolgensma?
High cost, limited diagnosis rates, and regional reimbursement policies are significant barriers.
5. How might future innovations affect Price projections?
Next-generation therapies, pricing reforms, or biosimilar entry could reduce prices or alter market share.
References
[1] Food and Drug Administration. (2019). FDA approves Zolgensma for treatment of spinal muscular atrophy in pediatric patients.
[2] IQVIA. (2022). Global sales data for gene therapies.
[3] Pharma Intelligence. (2023). SMA market analysis and projections.
